Drug Profile
KRL 103
Alternative Names: KRL-103Latest Information Update: 17 May 2016
Price :
$50
*
At a glance
- Originator Krele Pharmaceuticals
- Developer Tonix Pharmaceuticals Inc
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 11 Nov 2010 Krele Pharmaceuticals is now called TONIX Pharmaceuticals
- 26 Mar 2009 Clinical trials in Sleep disorders in USA (unspecified route)